Effect of rosiglitazone on cisplatin-induced nephrotoxicity

REFERENCES

• Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa T. Adverse effects of anti-tumor drug, cisplatin on rat kidney mitochondria: Disturbances in glutathione peroxidase activity. Biochem Biophys Res Commun. 1989;159:1121–1127.
   PubMed Web of Science ®Google Scholar
• Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995;48:761–770.
   PubMed Web of Science ®Google Scholar
• Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin induced injury to renal tubular epithelial cells. Kidney Int. 2001;60:1726–1736.
   PubMed Web of Science ®Google Scholar
• Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin induced acute renal failure in rats. J Lab Clin Med. 1998;131:518–526.
   PubMed Web of Science ®Google Scholar
• Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol. 2005;16:1985–1992.
   PubMed Web of Science ®Google Scholar
• Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator activated receptors and inflammation. Pharmacol Ther. 2006;110:371–385.
   PubMed Web of Science ®Google Scholar
• Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341–367.
   PubMed Web of Science ®Google Scholar
• Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA. 2003;100:6712–6717.
   PubMed Web of Science ®Google Scholar
• Smeets PJ, Planavila A, van der Vusse GJ, van Bilsen M. Peroxisome proliferator-activated receptors and inflammation: Take it to heart. Acta Physiol (Oxf). 2007;191:171–188.
   PubMed Web of Science ®Google Scholar
• Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–86.
   PubMed Web of Science ®Google Scholar
• Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79–82.
   PubMed Web of Science ®Google Scholar
• Kopple JD, Ding H, Letoha A, L-carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant. 2002;17:2122–2131.
   PubMed Web of Science ®Google Scholar
• Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol. 2003;285:F610–F618.
   PubMed Web of Science ®Google Scholar
• Zahng B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 2007;72:5–7.
   Google Scholar
• Mishima K, Baba A, Matsuo M, Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med. 2006;40:1564–1577.
   PubMed Web of Science ®Google Scholar
• Marx N, Mach F, Sauty A, Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503–6508.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235–238.
   PubMed Web of Science ®Google Scholar
• Eligini S, Banfi C, Brambilla M, 15-Deoxy-delta 12,14-prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: Evidence for ERK1/2 signaling pathway blockade. Thromb Haemost. 2002;88:524–532.
   Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell. 2001;104:487–501.
   PubMed Web of Science ®Google Scholar
• van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med. 1996;74:13–33.
   PubMed Web of Science ®Google Scholar
• Qian Y, Li S, Ye S, Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats. J Endocrinol Invest. 2008;12:1069–1074.
   Google Scholar
• Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001;59:1899–1910.
   PubMed Web of Science ®Google Scholar
• Sivarajah A, Chatterjee PK, Patel NS, Agonists of peroxisome proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol. 2003;23:267–276.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim W, Moon SO, Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant. 2006;21:2096–2105.
   PubMed Web of Science ®Google Scholar